AbbVie's Risankizumab (Skyrizi) Approved to Treat Moderately to Severely Active Crohn Disease

Press/Media

Period	28 Jun 2022

Media coverage

Title	AbbVie's Risankizumab (Skyrizi) Approved to Treat Moderately to Severely Active Crohn Disease
Media name/outlet	Patient Care Online
Country/Territory	United States
Date	28/06/22
URL	https://www.patientcareonline.com/view/abbvie-s-risankizumab-skyrizi-approved-to-treat-moderately-to-severely-active-crohn-disease
Persons	Marla Dubinsky